In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against <i>Staphylococcus aureus</i>

<jats:title>ABSTRACT</jats:title> <jats:p> Due to increasing mupirocin resistance, alternatives for <jats:italic>Staphylococcus aureus</jats:italic> nasal decolonization are needed. Lauric acid monoesters combined with lactic, mandelic, malic, or benzoic acid are being evaluated as possible alternatives. We determined the in vitro activity of 13 lauric acid monoester (LAM) formulations and mupirocin against 30 methicillin-susceptible <jats:italic>S. aureus</jats:italic> (MSSA) isolates and 30 methicillin-resistant <jats:italic>S. aureus</jats:italic> (MRSA) isolates. We then used a murine model of MRSA nasopharyngeal colonization to compare the in vivo activity of mupirocin with three LAM formulations. MSSA and MRSA MIC <jats:sub>90</jats:sub> values were 0.25 μg/ml for mupirocin and ≤4 μl/ml for all LAM formulations tested. Hsd:ICR mice were challenged with 10 <jats:sup>8</jats:sup> CFU/naris MRSA. Five days later, <jats:italic>S. aureus</jats:italic> colonization was documented by culture. Treatment with bland, mupirocin, or one of three LAM ointments was then administered unblinded thrice daily for 2 days. Three days after treatment, both anterior nares were cultured for <jats:italic>S. aureus</jats:italic> . Administration of 128774-49E or 128774-53A was associated with greater eradication of MRSA carriage (24/34 [71%] or 33/40 [83%]) of animals, respectively) than bland ointment (12/38 [32%]) ( <jats:italic>P</jats:italic> < 0.005). 128774-53A administration resulted in greater MRSA carriage eradication than mupirocin (19/38 [50%]) ( <jats:italic>P</jats:italic> < 0.005) in this model. LAM formulations warrant evaluation for <jats:italic>S. aureus</jats:italic> nasal decolonization in humans. </jats:p>